Table 2 All cause and CRC-specific analysis for rank transformed glycans.

From: Glycosylation of plasma IgG in colorectal cancer prognosis

Glycan

ALL cause analysis

CRC-specific analysis

Dead

Survived

 

Dead

Survived

 

(N = 489)

(N = 740)

Model II (AJCC, age, sex, time between sample and surgery, operation type, BMI, CRP, n = 952)

(N = 385)

(N = 844)

Model II (AJCC, age, sex, time between sample and surgery, operation type, CRP, bmi, n = 971)

Mean (SD)

Mean (SD)

HR (95% CI)

p-value

q-value

Mean (SD)

Mean (SD)

HR (95% CI)

p-value

q-value

Total IgG glycans (neutral and charged); Measured

 GP4

26.39 (7.33)

23.87 (6.37)

1.28 (1.14, 1.43)

2.6 × 10−5

0.0008

26.20 (7.31)

24.27 (6.59)

1.23 (1.09, 1.40)

0.001

0.04

 GP6

6.34 (1.88)

5.79 (1.57)

1.19 (1.06, 1.34)

0.002

0.05

6.23 (1.85)

5.91 (1.63)

1.10 (0.97, 1.25)

0.14

0.99

 GP8

18.26 (2.21)

18.67 (1.81)

0.87 (0.78, 0.97)

0.01

0.18

18.33 (2.13)

18.59 (1.91)

0.92 (0.81, 1.04)

0.16

0.99

 GP9

9.38 (1.36)

9.83 (1.35)

0.83 (0.75, 0.92)

0.0003

0.009

9.46 (1.35)

9.74 (1.38)

0.90 (0.80, 1.01)

0.06

0.99

 GP10

5.45 (1.23)

5.48 (1.15)

0.93 (0.84, 1.04)

0.2

0.74

5.40 (1.19)

5.50 (1.18)

0.90 (0.80, 1.02)

0.11

0.99

 GP11

10.19 (3.13)

11.44 (3.13)

0.77 (0.68, 0.86)

9.6×10−6

0.0004

10.30 (3.19)

11.24 (3.15)

0.81 (0.71, 0.92)

0.002

0.06

 GP15

1.38 (0.41)

1.50 (0.43)

0.86 (0.77, 0.96)

0.007

0.133

1.38 (0.40)

1.49 (0.43)

0.86 (0.76, 0.98)

0.02

0.46

 GP18

7.78 (2.29)

8.47 (2.34)

0.79 (0.71, 0.89)

4.9×10−5

0.002

7.87 (2.31)

8.35 (2.34)

0.82 (0.72, 0.93)

0.002

0.06

 GP19

1.87 (0.38)

1.90 (0.39)

0.98 (0.89, 1.08)

0.7

0.74

1.87 (0.37)

1.90 (0.39)

1.00 (0.90, 1.12)

0.98

0.99

Sialylation; Derived

 FGS/(FG+FGS)

24.78 (3.20)

24.95 (3.10)

0.93 (0.84, 1.03)

0.18

0.74

24.84 (3.24)

24.90 (3.09)

0.90 (0.80, 1.01)

0.08

0.99

 FBGS/(FBG+FBGS)

32.83 (6.17)

32.58 (6.34)

1.04 (0.94, 1.15)

0.47

0.74

32.93 (6.13)

32.56 (6.34)

1.05 (0.94, 1.19)

0.38

0.99

 FGS/(F+FG+FGS)

16.35 (3.63)

17.35 (3.61)

0.81 (0.72, 0.90)

0.0001

0.003

16.47 (3.64)

17.17 (3.63)

0.82 (0.72, 0.92)

0.001

0.04

 FBGS/(FB+FBG+FBGS)

21.21 (4.88)

21.82 (4.96)

0.95 (0.86, 1.05)

0.3

0.74

21.38 (4.93)

21.66 (4.94)

0.99 (0.88, 1.11)

0.8

0.99

 FG2S1/(FG2+FG2S1+FG2S2)

40.18 (2.99)

39.51 (2.77)

1.06 (0.95, 1.18)

0.28

0.74

40.22 (3.05)

39.57 (2.77)

1.00 (0.89., 1.13)

0.99

0.99

 FBG2S1/(FBG2+FBG2S1+FBG2S2)

37.02 (3.87)

36.41 (3.97)

1.12 (1.01, 1.24)

0.03

0.51

37.11 (3.80)

36.44 (3.99)

1.17 (1.04, 1.31)

0.009

0.25

Bisecting GlcNAc; Derived

 FBStotal/FStotal

0.30 (0.08)

0.28 (0.07)

1.19 (1.06, 1.33)

0.002

0.05

0.30 (0.07)

0.29 (0.08)

1.17 (1.03, 1.33)

0.02

0.46

 FBS1/FS1

0.17 (0.05)

0.16 (0.05)

1.18 (1.06, 1.32)

0.003

0.07

0.17 (0.05)

0.16 (0.05)

1.19 (1.05, 1.35)

0.006

0.17

 FBS1/(FS1+FBS1)

0.14 (0.04)

0.14 (0.03)

1.19 (1.06, 1.32)

0.002

0.05

0.14 (0.03)

0.14 (0.03)

1.19 (1.06, 1.35)

0.005

0.15

 FBS2/FS2

1.35 (0.32)

1.27 (0.30)

1.17 (1.05, 1.31)

0.005

0.11

1.33 (0.32)

1.29 (0.30)

1.10 (0.98, 1.25)

0.12

0.99

 FBS2/(FS2+FBS2)

0.56 (0.06)

0.55 (0.06)

1.17 (1.05, 1.30)

0.005

0.11

0.56 (0.06)

0.55 (0.06)

1.10 (0.97, 1.25)

0.13

0.99

Neutral IgG glycans; Measured

 GP4n

32.33 (8.02)

29.56 (7.02)

1.28 (1.14, 1.43)

2.6×10−5

0.0008

32.14 (8.00)

29.98 (7.24)

1.24 (1.09, 1.41)

0.001

0.04

 GP6n

7.78 (2.07)

7.18 (1.76)

1.17 (1.05, 1.31)

0.006

0.12

7.65 (2.07)

7.31 (1.83)

1.08 (0.94, 1.22)

0.27

0.99

 GP8n

22.59 (3.09)

23.32 (2.52)

0.83 (0.74, 0.92)

0.001

0.028

22.71 (3.01)

23.18 (2.66)

0.87 (0.77, 0.98)

0.02

0.46

 GP9n

11.60 (1.81)

12.28 (1.75)

0.79 (0.71, 0.88)

1.5×10−5

0.0005

11.72 (1.81)

12.14 (1.79)

0.85 (0.76, 0.97)

0.01

0.26

 GP10n

6.73 (1.54)

6.85 (1.46)

0.90 (0.81, 1.01)

0.06

0.74

6.68 (1.49)

6.85 (1.50)

0.88 (0.77, 0.99)

0.03

0.66

 GP14n

12.70 (4.29)

14.39 (4.37)

0.76 (0.68, 0.86)

7.4×10−6

0.0003

12.86 (4.38)

14.11 (4.38)

0.80 (0.71, 0.92)

0.001

0.04

 GP15n

1.72 (0.54)

1.89 (0.59)

0.85 (0.76, 0.95)

0.003

0.07

1.72 (0.53)

1.87 (0.59)

0.85 (0.75, 0.97)

0.01

0.26

Galactosylation; Derived

 G0n

41.15 (9.19)

37.69 (8.09)

1.31 (1.16, 1.47)

5.5×10−6

0.0002

40.83 (9.18)

38.26 (8.36)

1.24 (1.09, 1.41)

0.001

0.04

 G1n

42.72 (4.71)

44.26 (3.56)

0.78 (0.69, 0.87)

1.3×10−5

0.0005

42.90 (4.63)

43.99 (3.83)

0.82 (0.72, 0.94)

0.003

0.09

 G2n

15.65 (5.00)

17.61 (5.15)

0.78 (0.69, 0.87)

2.4×10−5

0.0008

15.79 (5.09)

17.30 (5.16)

0.81 (0.71, 0.93)

0.002

0.06

Core fucosylation and bisecting GlcNAc; Derived

 Fn

79.47 (3.74)

79.77 (3.46)

0.96 (0.86, 1.07)

0.48

0.74

79.68 (3.70)

79.63 (3.52)

1.02 (0.90, 1.15)

0.77

0.99

 FG0n/G0n

78.81 (4.29)

78.69 (4.11)

1.04 (0.93, 1.16)

0.46

0.74

79.01 (4.23)

78.62 (4.16)

1.10 (0.97, 1.24)

0.13

0.99

 FG1n/G1n

80.03 (3.79)

80.45 (3.56)

0.94 (0.85, 1.05)

0.31

0.74

80.24 (3.73)

80.30 (3.62)

1.00 (0.89, 1.14)

0.94

0.99

 FBn

17.29 (3.20)

16.97 (2.90)

1.02 (0.91, 1.14)

0.73

0.74

17.10 (3.15)

17.09 (2.97)

0.95 (0.84, 1.08)

0.44

0.99

 FBG0n/G0n

19.15 (3.88)

19.30 (3.65)

0.94 (0.84, 1.05)

0.25

0.74

18.98 (3.81)

19.36 (3.70)

0.89 (0.79, 1.01)

0.07

0.99

 FBG1n/G1n

18.20 (3.46)

17.82 (3.25)

1.04 (0.93, 1.16)

0.5

0.74

18.01 (3.39)

17.96 (3.32)

0.97 (0.86, 1.10)

0.64

0.99

 FBn/Fn

0.22 (0.05)

0.21 (0.05)

1.02 (0.92, 1.14)

0.68

0.74

0.21 (0.05)

0.21 (0.05)

0.95 (0.84, 1.08)

0.47

0.99

 FBn/Fn total

17.88 (3.38)

17.55 (3.07)

1.02 (0.92 , 1.14)

0.68

0.74

17.68 (3.33)

17.68 (3.14)

0.96 (0.85, 1.09)

0.5

0.99

 Fn/(Bn +FBn)

4.65 (1.09)

4.71 (1.01)

0.98 (0.88, 1.09)

0.74

0.74

4.71 (1.06)

4.68 (1.03)

1.05 (0.92, 1.18)

0.47

0.99

  1. Q value represents the adjusted p-values using the false discovery rate method (Benjamini–Hochberg procedure).
Back to article page